Tetraspanins including CD9, CD37, CD63, and CD151 are linked to cellular adhesion, cell differentiation, migration, carcinogenesis, and tumor progression. The aim of the study was to detect, quantify, and evaluate the prognostic value of these tetraspanins in Merkel cell carcinoma and to study the regulation of CD9 mRNA expression in Merkel cell carcinoma cell lines in detail. Immunohistochemical staining of 28 Merkel cell carcinoma specimens from 25 patients showed a significant correlation of CD9 (P ¼ 0.03) and CD151 (P ¼ 0.043) expression to overall survival. CD9 and CD63 expression correlated significantly to patients' disease-free interval (P ¼ 0.017 and P ¼ 0.058). Of primary Merkel cell carcinoma tumors, 42% were CD9 positive in contrast to only 21% of the subcutaneous in-transit metastases. Characterization of the 5 0 untranslated region (UTR) of the CD9 mRNA from two cultured Merkel cell carcinoma cell lines revealed the presence of two major RNA species differing only in the length of their 5 0 termini (183 versus 102 nucleotides). In silico analysis of the long CD9 mRNA predicted a 5 0 UTR folding pattern blocking ribosomal scanning and translation. Quantitative data by real-time RT-PCR not only indicated a reduction of CD9 mRNA but also a distinct quantitative shift toward the long 5 0 UTR in CD9 receptor negative cells. These observations provide an example for a posttranscriptional fine-tuning of CD9 gene expression in tumor cells.
regulating integrin trafficking and, therefore, is indicative for a poor prognosis, eg in non-small cell lung cancer. 8 CD63 shows also a broad tissue distribution and is predominantly localized in cytoplasmic lysosomes. [10] [11] [12] It is strongly expressed in early melanoma and downregulated in later stages and, thus, a good prognosis factor for this malignancy. 10, 13 CD37 is only expressed to a substantial extent in MHC class II-enriched compartments of B cells and usually regulates the IgA response. 10, 14 It is a reliable marker for malignancies derived from mature B cells. 15 CD9 is expressed in numerous tissues and has a pivotal role in cell adhesion, motility, and eggsperm fusion. 10, 16 It usually suppresses tumor progression and metastasis by inhibition of tumor proliferation and survival. 9 Owing to its multitude of different functions in various tissues, the regulation of CD9 gene expression is of particular interest. 10 Therefore, we decided to analyze CD9 mRNA expression in Merkel cell carcinoma cell lines in detail. The genome structure of CD9 revealed the presence of a GC-rich promoter preceding the CD9 coding region. 17 In contrast to a conventional TATAand CAAT-box-containing promoter, which rather fixes the transcription start site, GC-rich promoters are prone for multiple mRNA initiation sites, leading to a population of mRNA species with different 5 0 termini. 18, 19 Efficient mRNA translation is-besides several other constraints-substantially dependent on a supportive RNA folding pattern of the 5 0 untranslated region (UTR) usually preceding eukaryotic mRNA translation initiation codons. 20 
Long 5
0 UTRs with complex and stable RNA secondary structures and short open-reading frames-which is the case with CD9 mRNA-inhibit ribosomal scanning and translation. 17, 21 The aim of this study was to establish the expression patterns of the tetraspanins CD9, CD37, CD63, and CD151 in Merkel cell carcinoma tissue samples and to study the regulation of CD9 mRNA expression in Merkel cell carcinoma cell lines in detail. We provide evidence that the expression of these tetraspanins is of prognostic relevance concerning survival time and disease-free interval and supplies information about the metastatic potential of Merkel cell carcinoma tumors. Analysis of CD9 gene expression in Merkel cell carcinoma cell lines provides insights in how cells may fine-tune CD9 protein expression with high fidelity.
Materials and methods
All reagents were of molecular biology grade provided by Sigma-Aldrich (St Louis, MO, USA), unless otherwise stated. Reaction tubes (1.5 and 2 ml; Biopur) were from Eppendorf (Hamburg, Germany). All other consumables were from Sarstedt (Nü mbrecht, Germany).
Patients
Samples of patients with Merkel cell carcinoma were collected from the Departments of Otorhinolaryngology, Head and Neck Surgery and Dermatology of the Medical University of Vienna. All patients were treated during the years 1991 and 2005. The clinical data are summarized in Table 1 . All samples were staged according to the most commonly used system (stage I, local disease; stage II, loco regional disease; stage III, distant disease). 22 
Tissue Specimens
Twenty-eight Merkel cell carcinoma tissue samples from 25 patients were included in the study. Of these specimens, 13 were primary tumors and 15 were metastases. In particular, of these 15 specimens, 7 biopsies were subcutaneous in-transit metastases, 7 metastatic lymph nodes, and 1 recurrent primary tumor (Table 1 ). All tissue samples from our department and the Department of Dermatology suspected for Merkel cell carcinoma are routinely sent to the Department of Pathology, where diagnosis of all Merkel cell carcinomas has been verified by CK20 staining before the specimens were included in our study. CK20 staining of Merkel cell carcinoma tissue samples is routinely requested and performed at the Department of Pathology. Thus, all charts have been thoroughly checked before the start of our study.
Tissue Microarray
Hematoxylin-eosin-stained tissue sections (2-3 mm) from each sample were evaluated for suitability before enrollment into the study. The following inclusion criteria were applied: size (1-2 mm in depth and at least 5 mm in length and width), appropriate fixation, absence of significant electrosurgical device lesions, signs of acidic decalcifying agents, and the presence of usable tissue in each block. Each hematoxylin-eosin-stained slide was revaluated by our pathologists (PP, JP) and mapped to identify the specific areas for tissue acquisition to build the tissue microarrays. These arrays were constructed with a Beecher manual tissue arrayer (MTA-1; Beecher Instruments, WI, USA) according to Kononen et al 23 . The diameter of the core was 0.6 mm. Three cores were used per patient.
Immunohistochemistry
Dewaxed and rehydrated tissue microarrays were subjected to antigen retrieval in a microwave oven (600 W) using the appropriate buffer ( Table 2) . Blocking of unspecific binding was achieved with 5% TBS/BSA (Sigma-Aldrich, Germany) for 1 h at room temperature. Application of the primary antibody (Table 2 ) and appropriate negative and positive 
Specimen Classification Based on Immunohistochemical Results and Morphological Features
The immunoreactivity score proposed by Sinicrope et al 24 to evaluate both the intensity of immunohistochemical staining and the proportion of the stained tumor cells was applied. The staining intensity was subclassified as follows: 1, weak; 2, moderate; or 3, strong. The positive cells were quantified as a percentage of the total number of tumor cells and the proportions were assigned to one of five categories: 0, o5%; 1, 5-25%; 2, 26-50%; 3, 51-75%; and 4, 475%. The percentage of positivity of the tumor cells and the staining intensity were then multiplied to generate the immunoreactivity score for each of the tumor specimens. A mean immunoreactivity score was calculated from the three samples per patient. The expression pattern of each marker in the complete tumor samples was determined independently by two investigators (MB and BME). An attempt to avoid observer bias was made by repeating the evaluation of protein expression at two different time points and without knowledge of patients' clinical data.
Cell Culture
The Merkel cell carcinoma cell lines MCC13 and MCC1412 were grown to a confluent monolayer in 175 cm 2 polystyrene flasks with ventilation caps (Sarstedt) in RPMI 1640 medium containing 10% fetal calf serum and 100 U/ml penicillin and 100 mg/ ml streptomycin (all reagents from Life Technologies, Paisley, Scotland) at 371C in a humidified atmosphere of 5% CO 2 until confluence. The tongue carcinoma cell lines SCC9 and SCC25 were used as reference cell lines and for the establishment of the GeneRacer technology because they were more easy to handle and readily obtainable from the American Type Culture Collection. Cells were counted in a Casy1 cell counter (Schärfe Systems, Reutlingen, Germany).
RNA Isolation
RNA was isolated from approximately 1 Â 10 8 cells grown in cell culture using the RNeasy Midi Kit (Qiagen, Hilden, Germany) and the total RNA isolation protocol for animal cells according to the manufacturer's recommendations with minor modifications. 25 In brief the cells were harvested by transferring 4 ml of ice-cold buffer RLT containing 0.143 M b-mercaptoethanol evenly onto the monolayer. The cells were collected by quickly scraping the surface of the vessel with a rubber policeman, pipetted into a 50 ml polypropylene tube (Sarsted), and stored on ice. The cell lysate was homogenized by centrifugation (13 000 g/2 min; Eppendorf 5417 R) through Qiashredder columns (Qiagen) . The flow through was collected in 15 ml polypropylene tubes, mixed with 4 ml of ice-cold 70% ethanol (SigmaAldrich), transferred to an RNeasy column, and centrifuged. DNA was digested on column after washing the anion exchange resin with 2 ml of buffer RW1 by the addition of 160 ml of a DNase I incubation mix (approximately 55 Kunitz units resuspended in buffer RDD; Qiagen). After incubation for 15 min at room temperature the column was washed with 2 ml buffer RW1. Buffer RPE was applied onto the RNeasy column twice (2.5 ml each). The column was dried by a third centrifugation step using a new collection tube.
RNA was eluted twice with RNase-free water (200 and 150 ml, each), aliquoted, and immediately stored on À701C. All centrifugation steps were performed at 5000 g for 5 min at room temperature in a Hettich Rotanta 46 device unless otherwise stated. The quality of the RNA isolate was assessed by calculating the absorption quotient at 260 and 280 nm. The integrity of the RNA was checked on a native 1% agarose gel after staining with ethidium bromide. 
Reverse Transcription
RNA was reverse transcribed using the RevertAid H Minus First Strand cDNA synthesis kit (Fermentas, St Leon-Rot, Germany) according to the manufacturer's protocol. 26 All steps were performed quickly on ice. Briefly, 10 ml of total RNA (0.5 mg/ml) was transferred into a 0.2 ml PCR clean reaction tube (Eppendorf). 1 ml of the oligo dT 18 primer solution (0.5 mg/ml) and 1 ml RNase-free water were added, mixed, and spun down. The RNA solution was denatured for 5 min at 701C on a thermocycler (Hybaid PCR Express HBPX110, Heidelberg, Germany) and immediately chilled on ice. The RT master mix was prepared by adding 4 ml of 5 Â reaction buffer, 1 ml Ribolock ribonuclease inhibitor (20 U), and 2 ml of a 10 mM dNTP mix per reaction. The solution was gently mixed by pipetting and spun down. The RT master mix (7 ml) was transferred to 12 ml denatured RNA solution and incubated at 371C for 5 min on the thermocycler. Then 1 ml RevertAid H Minus M-MuLV RT (200 U/ml) was added and the assay was incubated for 60 min at 421C. The reaction was stopped by a heating step to 701C for 10 min. The cDNA was aliquoted and stored at À201C.
Quantitative Real-Time PCR
Quantitative real-time PCR was performed on the LightCycler 1.5 system using glass capillaries and the Quantitect SYBR Green PCR mastermix (Qiagen). The PCR assay contained 5 ml of the 2 Â Quantitect mastermix, 0.3 ml of the left and right primer achieving a final concentration of 0.3 mM, each, and 2.4 ml RNase-free water. This mixed solution (8 ml) was pipetted into a glass capillary followed by the addition of 2 ml of the cDNA containing the target sample dilution. After a short centrifugation (3000 r.p.m./30 s) the capillaries were transferred into the LightCycler. The amplification conditions were as follows: an initial denaturation at 951C for 15 min was followed by 45 cycles of 941C/15 s, an annealing step at 601C for 20 s, and an elongation for 10 s at 721C. The target was identified by a melting curve analysis using the continuous mode and a temperature profile from 70 to 951C in increments of 0.11C. The melting curves were verified by agarose gel electrophoresis. The relative abundance of long (mRNA3) and short (mRNA1) CD9 mRNA in MCC cell lines was established with absolute quantification using an external standard curve. A CD9 5F74/CD9 gr18 PCR amplicon, which was excised from an agarose gel and purified with the Wizard SV Gel Clean-Up System (Promega, Leiden, the Netherlands) served as external standard. The standard curve was created by semilogarithmic dilutions of the spectrophotometrically quantified amplicon starting with 10 000 and closing with 80 copies per PCR assay. Each dilution was analyzed in triplicates. Dilutions of the RT assays Primers were constructed with Vector NTI 7.1 software suite (Informax/Invitrogen, Carlsbad, CA, USA) using the GenBank entry NM_001769 and the NCBI reference sequence NT_009759.15 as target sequences.
Characterization of the CD9 mRNA 5 0 UTR
The transcription initiation site of the CD9 mRNA was characterized using the GeneRacer kit (Invitrogen) and the protocol recommended by the manufacturer. 27 The application of the GeneRacer methodology was based upon rapid amplification of cDNA ends and guaranteed full-length 5 0 ends of RNA transcripts by capturing only 5 0 capped mRNAs avoiding truncated RNAs or other artifacts. The agarose gel extracted amplicons (Wizard SV Gel Clean-Up System; Promega) were cloned into the pCR2.1 vector using the TOPO TA cloning kit from Invitrogen. Plasmid DNA was isolated from 20 randomly chosen bacterial clones with the Qiaprep Spin Miniprep kit (Qiagen) . The inserts were sequenced at VBC Genomics (Vienna, Austria) using the dideoxy chain termination technology.
RNA Secondary Structure Calculation
The secondary structure of the CD9 5 0 UTR mRNA was calculated with the software RNAshapes and displayed with Pseudoviewer2.5. The results were validated by reanalysis with RNAstructure 4.2 applying default values based on the Zuker algorithm for free energy minimization using the nearest neighbor parameters of Turner and coworkers.
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Statistical Analysis
The overall survival was defined as the period from the patient's first visit to the outpatient department until the end of the study (1 May 2009). The diseasefree interval was defined as the period from the patient's first visit to the final date of the study, or the period from the patient's first visit to the outpatient department to the date of recurrent disease being diagnosed. The overall survival and 
Results
Clinical Data
A total of 28 tissue specimens from 25 patients (13 men, 12 women; aged 57-96 years; median 77 years) with diagnosed Merkel cell carcinoma were analyzed for protein expression patterns of CD9, CD37, CD63, and CD151. Fifteen tumors (53%) were located in the head and neck region and eight (29%) on the extremities. One primary tumor (4%) and three metastasis specimens (11%) could not be localized. Twenty patients (80%) presented with early disease (Stage I), three with Stage II (12%), and two with Stage III (8%). At the completion of the study, seven (28%) were alive without disease and one (4%) was alive with disease. Eleven died of the disease (44%) and six died of other causes (24%). Details on clinical data are provided in Table 1 .
Microscopy
Two distinct types of Merkel cell carcinomas could be distinguished as already described by Sur et al.
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Nine samples showed morphology similar to classical small cell carcinoma. In 18 samples the carcinoma cells were significantly bigger (larger than 3 lymphocytes) and showed high mitotic activity and multiple nucleoli. In five samples, both morphologies were present.
Immunohistochemistry
A typical immunohistochemical staining of the tetraspanins CD9, CD37, CD63, and CD151 in a tissue array of Merkel cell carcinoma is depicted in Figure 1 . A strong positive staining signal was obtained in two cases for CD9 (specimen 13/12) and CD151 (specimen 2/2), both from primary tumors. Concerning CD9 expression, 15% of the samples produced a weak, 12% a moderate, and 4% a strong signal. No CD9 signal was obtained from 69% of all samples where data could be retrieved. CD37 was weakly positive with 60% of the samples, but only 8% showed a moderate signal and no sample was strongly positive. 32% of the samples were negative for CD37. CD63 was weakly positive in 50% of the tested samples and 27% showed a moderate staining pattern. No sample was strongly positive for CD63, but 23% were negative. CD151 displayed a weak signal in 36%. Of the samples, 21% were moderately stained by CD151-specific antibodies. No CD151% specific signal could be retrieved from 39% of the samples.
Follow-up samples were collected from three patients. Three specimens were in-transit skin metastases (11/11, 12/11, and 16/15). Two specimens were from lymph nodes (23/21 and 24/21). Specimen 17/15 from a primary tumor was CD9 and CD37 negative, but showed signals for CD63 and CD151. Specimen 16/15 was isolated 1 year later from an intransit metastasis and had lost CD63 but gained CD37 (Figure 2) . The expression patterns of CD9, CD37, CD63, and CD151 including tumor type and tumor stage of the analyzed tissue specimens are displayed in Figure 2 . A quantitative evaluation of the immunohistochemistry results is compiled in Table 3 .
CD9 was significantly more prevalent on primary tumors (42%) compared to subcutaneous metastatic in-transit and lymph node metastases (21%). The expression patterns of CD37, CD63, and CD151 showed no obvious difference between primary and metastatic tumor specimens. The establishment of a correlation between tumor stage and tetraspanin expression patterns was not feasible (Figure 2 and Table 3 ).
Prognostic Evaluation of the Tissue Expression Data
After multivariate analysis, CD9 overexpression significantly correlated to prolonged overall survival of the patient (P ¼ 0.03) and the disease-free interval (P ¼ 0.017). Univariate analysis showed that diseasefree interval correlates to CD63 (P ¼ 0.058) and overall survival to CD151 overexpression (P ¼ 0.043) ( Table 3 ).
CD9 5
0 UTR mRNA
GeneRacer analysis
GeneRacer characterization of the 5 0 UTR of the CD9 mRNA from Merkel cell carcinomas revealed the presence of two major mRNA species: long CD9 mRNAs with 5 0 UTRs of 183 nucleotides (nts) and shorter mRNAs with 5 0 UTRs of 102 nts ( Figure 3 ).
Computational analysis
Computational analysis of the short 102 nts CD9 5 0 UTR predicted two major stem-loop structures and 17 GC base pairs preceding the starting point for translation. The structure showed a minimum free energy of À23.09 kcal/mol and a shape probability of P ¼ 0.016 (Figure 4 ). In contrast, the predicted secondary structure of the 183 nts 5 0 UTR composed of 4 major stem-loop elements and 36 GC base pairs preceding the translation initiation site. The folding pattern leads to a calculated minimum free energy of À58.6 kcal/mol (P ¼ 0.0013) (Figure 4) . Secondary structure analysis of CD9 mRNA 5 0 UTRs of 80 and 172 nts (proposed by Rubinstein et al 17 ) revealed two major stem-loop structures for the 80 nts fragment Figure 1 The immunostaining of tetraspanin molecules in a tissue microarray of Merkel cell carcinoma. Positive expression of CD9, CD37, CD63, and CD151 is shown on panels a-d and negative staining on panels e-h. CD9 (a) and CD151 (d) show the typical membranous staining pattern whereas CD37 and CD63 were expressed in the cytoplasm. All photomicrographs were taken at a magnification Â 200. Table 4 ). The presented absolute CD9 mRNA copy numbers per mg of total isolated RNA were mean values of 13 PCR runs from 4 independent experiments. A quantitative shift from short ( ¼ RNA1) to long ( ¼ RNA3) mRNAs obviously correlating with a loss of CD9 on the cell surface and an increase of the metastatic potential of the analyzed cells were substantiated by RNA3/RNA1 ratios as follows: MCC13 ¼ 0.12; MCC1412 ¼ 0.09; SCC9 ¼ 0.05; SCC25 ¼ 0.03 (Table 4) .
Discussion
We could establish a correlation between CD9 overexpression and a longer survival time and disease-free interval for patients suffering from Figure 2 Twenty-eight Merkel cell carcinoma specimens from 25 patients were immunohistochemically screened for tissue expression of the tetraspanins CD9, CD37, CD63, and CD151. The presented overall immunoreactivity score (negative, weak, moderate, strong) was calculated by multiplication of the staining intensity (1, weak; 2, moderate; or 3, strong) with the percentage of stained cells (0, o5%; 1, 5-25%; 2, 26-50%; 3, 51-75%; and 4, 475%) in the specimen. From 112 tests, 105 yielded interpretable results. Of all results, 76% were negative or showed only a weak immunoreactivity, 16% were moderately reactive. Two specimens showed a strong reaction. NA ¼ no data available.
Merkel cell carcinoma by immunohistochemical staining of the respective tissue samples. This observation corresponds with previous reports showing that the level of CD9 expression is predictive for a disease-free survival in patients with squamous cell carcinoma of the head and neck 32, 33 and that CD9 is a good prognosis factor in breast, 34 lung, 35 colon, 36 and pancreas cancer. 37 In all of these malignancies, a downregulation of CD9 leads to tumor progression and to metastasis. We can extend these findings to Merkel cell carcinoma because we observed significantly more primary tumor tissue samples displaying CD9 protein expression than were CD9 negative. Loss of CD9 expression was substantially more prevalent in subcutaneous Merkel cell carcinoma in-transit and lymph node metastases compared to primary tumor tissue samples. These data are in good correlation with common knowledge because CD9 is known to be a potent suppressor of tumor progression by inhibition of integrin-mediated motility. 9 We observed a clear correlation between CD63 expression in Merkel cell carcinomas and the disease-free interval of the patients. This observation is supported by the discovery that CD63 is strongly expressed in early stages of melanoma and would be downregulated only at later stages when the tumor starts to progress. In the reported case, CD63 expression analysis provided a good prognosis tool for evaluating the status of melanoma. 13 We could show that the level of expression of CD151 in Merkel cell carcinoma correlates inversely to the survival of the patient. This is in line with reports that identified CD151 as tumor progression marker. CD151 inhibits tumor cell intravasation 38 and promotes cell migration by regulation of integrin movements. 39 Sauer et al 7 reported a coupling of the expression of CD9, CD63, and CD151 in breast cancer cells and a reduction of expression below certain thresholds were predictive at least for in vitro invasiveness. We could not observe a coupled expression of tetraspanins in Merkel cell carcinoma tissue samples: the evaluation of marker combinations was diagnostically not more conclusive concerning survival or disease-free interval than analysis of a single tetraspanin. The analysis of CD37 tissue expression patterns was not of prognostic relevance.
We discovered the coincident presence of two CD9 mRNA species in Merkel cell carcinomas, which differed only in the length of their 5 0 UTRs. In silico analysis of the long 183 nts 5 0 UTR revealed a high GC content, a complex secondary structure comprising of stable stem-loops, and a short openreading frame coding for 9 amino acids. These data are characteristic for 5 0 UTRs that inhibit ribosomal translation. 21 The short 5 0 UTR of 102 nts is predicted to produce a folding pattern, which allows an optimal translation of the CD9 mRNA. 21 Quantitative analysis of each short and long CD9 mRNA species revealed not only an overall reduction of CD9 mRNAs in metastasizing cells but also a subtle shift from shorter to longer 5 0 UTRs. This implies the conclusion that not only a reduction of the absolute quantity of CD9 mRNA can reduce the amount of the produced CD9 protein: A shift from shorter to longer 5 0 UTRs had a similar effect and could reduce protein assembly due to blocking of protein translation by inhibiting eukaryotic ribosomal assembly. 40, 41 This quantitative shift allows a subtle fine-tuning of the expression of CD9 by gradually changing the ratio of long and short mRNAs. A regulation of protein expression by structured 5 0 UTRs has been described for several prominent housekeeping and proto-oncogenes, such as the transforming growth factor b-family, brca1, c-mos, bcl-2, and mdm2. 21, 41 Complex 5 0 UTR folding patterns may also offer the opportunity for finetuning of gene expression on the posttranscriptional level. 41 Variable CD9 mRNA species ratios may be also of certain relevance concerning the control of CD9 expression in normal tissue because this receptor is involved in a multitude of cellular interactions, such as egg-sperm fusion, 16 activating platelets, 17 suppressing motility and promoting adherence to the surrounding matrix by interactions with integrins, signaling proteins, and immunoglobulin superfamily members. 9 Regulation of CD9 gene expression has been attributed to the acquisition and action of specific transcription factors, 17 CpG methylation of promoter regions 42 or to histone modifications, 43 which led to CD9 silencing at least in myeloma cell lines. But-to our knowledge-regulation of CD9 gene expression relying on posttranscriptional effects due to 5 0 UTRs with complex secondary structures has not been in discussion, yet. 21 Notwithstanding, a gradual change of the ratio of short and long 5 0 UTRs containing CD9 mRNAs may provide an additional molecular explanation how Merkel cell carcinomas are gradually transforming from tissue-bound tumor to aggressive metastatic cells.
We could show that the analysis of the expression profiles of CD9, CD63, and CD151 is of prognostic relevance and should help to establish therapy regimens tailored for patients who suffer from Merkel cell carcinoma. The proposed model of posttranscriptional regulation of CD9 gene expression may help to understand how CD9 is able to facilitate a multitude of diverse cellular functions in normal tissues and malignant diseases. 
